Lucicebtide

N/A

Report date: 2025/05/15 11:44:58
NME

Base Information

Drug NameLucicebtide
Drug Alias NameST-101(Sapience Therapeutics)
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionCCAAT/enhancer-binding protein beta inhibitors
TargetsCCAAT/enhancer-binding protein beta
Therapy Area/IndicationsMetastatic breast cancerProstatic NeoplasmsBrain Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSapience Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSapience Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerProstatic NeoplasmsBrain Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A